Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

91 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2014.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 19,758,262 shares of 104,661,494 outstanding shares and own 18.88% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), NQ HCIF GP, Ltd. (3,096,650 shares), FRANKLIN RESOURCES INC (2,754,139 shares), Polar Capital LLP (1,107,272 shares), Bank of New York Mellon Corp (1,023,422 shares), Visium Asset Management, LP (1,000,000 shares), Arrowpoint Asset Management, LLC (787,923 shares), JPMORGAN CHASE & CO (722,276 shares), ALLIANCEBERNSTEIN L.P. (575,906 shares), and BlackRock Fund Advisors (515,592 shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.